SAN DIEGO, USA - April 14, 2024 - PrecisePK, a leading figure in precision medicine, proudly announces its strategic collaboration with Pacific University Oregon, heralding a new era in precision medicine research and innovation.
This partnership signifies a significant stride towards the advancement of precision medicine education and research, as PrecisePK joins forces with Pacific University Oregon to harness state-of-the-art technology for the betterment of healthcare practices and patient outcomes.
Pacific University Oregon's esteemed School of Pharmacy boasts an extensive research program spanning various pharmaceutical disciplines, encompassing pharmacology, pharmaceutics, pharmacokinetics, medicinal chemistry, drug discovery, drug target validation, toxicology, natural products, infectious diseases, as well as research in cancer and cardiovascular disease. This vibrant research environment provides an optimal backdrop for PrecisePK to integrate its Bayesian Model-Informed Precision Dosing (MIPD) software and spearhead innovative research endeavors.
Dr. Anjum Gupta, CEO of PrecisePK, expresses his profound enthusiasm about the collaboration: "We are delighted to partner with Pacific University Oregon's School of Pharmacy, a distinguished institution at the forefront of pharmaceutical research. By uniting our proficiency in precision dosing with Pacific University Oregon's diverse research portfolio, our objective is to expedite advancements in precision medicine and elevate the standard of patient care."
Through this synergistic alliance, PrecisePK and Pacific University Oregon will collaborate on research initiatives aimed at optimizing drug dosing strategies, augmenting therapeutic outcomes, and advancing precision medicine across a spectrum of therapeutic areas.
In a parallel development towards personalized medicine, PrecisePK proudly unveils the launch of three groundbreaking drug models for Bayesian precision dosing: Methotrexate, Cyclosporine, and Infliximab. As part of the collaboration, Pacific University Oregon (PUO) will gain access to PrecisePK's new and expanded drug library. PrecisePK's comprehensive coverage spans cardiology, infectious diseases, oncology, neurology, and various other pertinent therapeutic domains. Furthermore, additional drug models including Adalimumab, Sirolimus, and Everolimus are currently in the pipeline for development at PrecisePK.
About Pacific University Oregon
Pacific University Oregon stands as a premier educational institution offering a diverse array of undergraduate, graduate, and professional programs. The School of Pharmacy at Pacific University Oregon is renowned for its comprehensive research program, encompassing pharmacology, pharmaceutics, pharmacokinetics, medicinal chemistry, drug discovery, drug target validation, toxicology, natural products, infectious diseases, and research in cancer and cardiovascular disease.
About PrecisePK
PrecisePK is a global leader in therapeutic drug monitoring software for Bayesian model-informed precision dosing, empowering clinicians to achieve personalized drug dosing and uphold patient care seamlessly. With an unwavering commitment to advancing precision medicine, PrecisePK continues to redefine healthcare treatments and outcomes through cutting-edge technology and collaborative research efforts.
